Global Psychedelic therapeutics market is projected to grow at an annualized rate of ~15%, (till 203

Roots Analysis has done a detailed study on Global Psychedelic Therapeutics Market, 2020-2030” covering key aspects of the industry and identifying potential future growth opportunities

To order this 250+ page report, which features 120+ figures and 135+ tables, please visit this- https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html  Key Market Insights Nearly 70 players from across the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds, such as ketamine and psilocybinThe pipeline features product candidates based on a variety of psychedelic drug classes, which are being investigated for a wide range of target disease indications, and having different routes of administrationFrom a global perspective, this industry is anticipated to evolve significantly over the next few years as federal / regional regulators in different nations are gradually convinced of the clinical significance of this product classSeveral organizations, having realized the untapped opportunity within this emerging segment of psychedelic therapeutics, have awarded grants of over USD 275 million across 500+ instances between 2015-2020Several trials evaluating various psychedelic compounds against a wide range of therapeutic indication have been registered in the recent pastThe growing interest is also reflected in the partnership activity since 2017; a number of different types of deals involving various drug classes have been established across multiple geographiesPresently, North American companies are actively consolidating their indigenous presence through strategic acquisitions; key value drivers behind such deals include both portfolio and geographical expansionA number of eminent scientists from renowned universities have emerged as key opinion leaders in this domain, owing to their active involvement in clinical development efforts related to interventions based on psychedelicsFuture market size, based on revenue reported from the sales of marketed and late stage psychedelic-based  therapies, is anticipated to be distributed across different therapeutic areas and key geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html

Table of Contents

1.PREFACE1.1.Scope of the Report1.2.Research Methodology1.3.Chapter Outlines

2.EXECUTIVE SUMMARY3.INTRODUCTION3.1.Chapter Overview3.2.History of Psychedelic Substance3.3.Potential Therapeutic Application of Psychedelic Substance3.4.Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use3.5.Future Opportunity

4.MARKET LANDSCAPE: PSYCHEDELIC THERAPEUTICS4.1.Chapter Overview4.2.Psychedelic Therapeutics: Marketed and Development Pipeline4.2.1. Analysis by Phase of Development4.2.2. Analysis by Type of Psychedelic Substance4.2.3. Analysis by Origin of Psychedelic Substance4.2.4. Analysis by Target Therapeutic Area4.2.5. Analysis by Type of Therapy4.2.6. Analysis by Route of Administration4.2.7. Analysis by Dosing Frequency

4.3.Psychedelic Therapeutics: List of Developers4.3.1. Analysis by Year of Establishment4.3.2. Analysis by Company Size 4. 3.3.Analysis by Location of Headquarters4.4.Grid Analysis: Distribution by Phase of Development, Origin of Psychedelic Substance and Location of Headquarters

5.COMPANY PROFILES

5.1.Chapter Overview

5.2.Celon Pharma

5.2.1.Company Overview

5.2.2.Financial Information

5.2.3.Psychedelic Therapeutics Portfolio

5.2.3.1.Esketamine DPI

5.2.4.Recent Developments and Future Outlook

5.3.iX Biopharma

5.3.1.Company Overview

5.3.2.Financial Information

5.3.3.Psychedelic Therapeutics Portfolio

5.3.3.1.Wafermine™ 

5.3.3.2.Unnamed (Ketamine)

5.3.4.Recent Developments and Future Outlook

5.4.MAPS Public Benefit

5.4.1.Company Overview

5.4.2.Financial Information

5.4.3.Psychedelic Therapeutics Portfolio

5.4.3.1.Unnamed (MDMA)

5.4.3.2.Unnamed (Ibogaine Hydrochloride)

5.4.3.3.Unnamed (LSD)

5.4.3.4.Unnamed (Ayahuasca)

5.4.4.Recent Developments and Future Outlook

5.5.MindMed

5.5.1.Company Overview

5.5.2.Psychedelic Therapeutics Portfolio

5.5.2.1.Unnamed (LSD)

5.5.2.2.Unnamed (MDMA)

5.5.2.3.18-MC

5.5.2.4.Unnamed (DMT)

5.5.2.5.Unnamed (LSD, MDMA)

5.5.3.Recent Developments and Future Outlook

5.6.Janssen Pharmaceuticals

5.6.1.Company Overview

5.6.2.Financial Information

5.6.3.Psychedelic Therapeutics Portfolio

5.6.3.1.SPRAVATO® 

5.6.4.Recent Developments and Future Outlook

5.7.Jazz Pharmaceutical

5.7.1.Company Overview

5.7.2.Financial Information

5.7.3.Psychedelic Therapeutics Portfolio

5.7.3.1.XYREM®

5.7.3.2.JZP-258

5.7.3.3.JZP-324

5.7.4.Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Chapter Overview

6.2. Scope and Methodology

6.3. Psychedelic Therapeutics: Clinical Trial Analysis

6.3.1. Analysis by Trial Registration Year

6.3.2. Analysis by Trial Phase

6.3.3. Analysis by Trial Recruitment Status

6.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled

6.3.5. Analysis by Study Design

6.3.6. Leading Trial Sponsors: Analysis by Number of Registered Trials

6.3.7. Leading Players: Analysis by Number of Registered Trials

6.3.8. Analysis by Trial Focus

6.3.9. Analysis by Target Therapeutic Area 

6.3.10. Popular Psychedelic Substance: Analysis by Number of Registered Trials 

6.3.11. Geographical Analysis by Number of Registered Trials 

6.3.12.  Geographical Analysis by Number of Patients Enrolled

7.CLINICAL TRIAL SITE ANALYSIS

7.1.Chapter Overview

7.2.Scope and Methodology

7.3.Psychedelic Therapeutics: Clinical Trial Site Analysis

7.3.1.Analysis by Geographical Location

7.3.1.1.Clinical Trial Sites in North America

7.3.1.1.1.Analysis by Trial Phase

7.3.1.1.2.Analysis by Target Therapeutic Area

7.3.1.1.2.Analysis by Trial Phase and Target Therapeutic Area

7.3.1.2.Clinical Trial Sites in Europe

7.3.1.2.1.Analysis by Trial Phase

7.3.1.2.2.Analysis by Target Therapeutic Area

7.3.1.2.2.Analysis by Trial Phase and Target Therapeutic Area

7.3.1.3.Clinical Trial Sites in Asia Pacific

7.3.1.3.1.Analysis by Trial Phase

7.3.1.3.2.Analysis by Target Therapeutic Area

7.3.1.3.2.Analysis by Trial Phase and Target Therapeutic Area

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

damon987 Member since April 7, 2021